MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. (Q43253684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Laurence Bonhomme-Faivre

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

6

Catherine Guettier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Bernard Paule

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Vincent Castagne

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Véronique Picard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

René Adam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Robert Farinotti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

28 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1066-1072

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-009-9336-3

11 February 2020

exact match

0 references

cites work

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-009-9336-3

MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients

21 January 2018

1 reference

12 December 2020

Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice

1 reference

12 December 2020

Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats

1 reference

12 December 2020

Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice

1 reference

12 December 2020

Predictive factors of response to anti-EGFR treatments in colorectal cancer

1 reference

12 December 2020

Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

Irinotecan pathway genotype analysis to predict pharmacokinetics

1 reference

12 December 2020

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene

1 reference

12 December 2020

Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats

1 reference

12 December 2020

In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells

1 reference

12 December 2020

Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples

1 reference

12 December 2020

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

12 December 2020

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

1 reference

12 December 2020

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

1 reference

12 December 2020

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

1 reference

12 December 2020

Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies

1 reference

12 December 2020

Pharmacogenetics of irinotecan toxicity

1 reference

12 December 2020

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

1 reference

12 December 2020

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

12 December 2020

MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.

1 reference

12 December 2020

10.1007/S12032-009-9336-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19862647%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 February 2020

1021095054

0 references

Fatcat ID

release_earrkhhuqfd7dbcwct7twxt74m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/earrkhhuqfd7dbcwct7twxt74m

24 November 2022

mapped directly with Wikidata item

1 reference